Applying Learnings From the SPECTREM Study to Clinical Practice

Panelists discuss how the SPECTREM study (Stein Gold, 2024) demonstrated guselkumab’s remarkable efficacy for moderate psoriasis in high-impact areas, with 74% of treated patients achieving clear/almost clear skin (Investigator’s Global Assessment [IGA] 0/1) at week 16 compared with just 12% on placebo, while importantly showing consistent effectiveness regardless of baseline body surface area (BSA)—suggesting that BSA alone shouldn’t determine treatment approach and validating biologic therapy for patients with limited but highly impactful disease.